Mollisupradin (Bromhexine Hydrochloride, Ephedrine Hydrochloride)

Bromhexine Hydrochloride acts on mucus glycoproteins, breaking down their structure and lowering viscosity. This makes the mucus less thick, allowing cilia in the respiratory tract to move it more efficiently toward the throat for expectoration.

The appropriate dose of Mollisupradin is determined by the prescribing healthcare professional based on the patient’s age, weight, severity of symptoms and any co‑existing medical conditions. Patients should follow the prescriber’s instructions and not alter the dose on their own.

Safety in pregnancy and lactation has not been fully established. The product should only be used if the potential benefit justifies the possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike single‑ingredient cough suppressants, Mollisupradin combines a mucolytic (bromhexine) with a sympathomimetic (ephedrine). This dual action both thins mucus and opens airways, offering a broader approach for patients with both productive cough and nasal congestion.

Mollisupradin should be stored at room temperature, below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight and excessive heat to maintain product stability.

Mollisupradin is taken orally, usually with a glass of water. The exact administration schedule—such as frequency and timing relative to meals—should follow the prescribing clinician’s directions.

Serious risks include arrhythmias, severe hypertension, allergic reactions such as anaphylaxis, seizures and myocardial infarction. Patients should seek immediate medical attention if they experience chest pain, rapid heartbeat, severe headache, difficulty breathing or signs of an allergic reaction.

Mollisupradin is contraindicated in individuals with known hypersensitivity to bromhexine, ephedrine or any excipients, as well as patients taking monoamine oxidase inhibitors. Caution is also advised for those with uncontrolled hypertension, certain thyroid disorders, or severe cardiovascular disease.